Businesshorizon Pharma (October 13th, 2016)
We are a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. We market nine medicines through our orphan, rheumatology and primary care business units. Our marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Horizon Pharma Plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH - Also Licenses Rights to Patents and Pending Applications Covering Methods for Treating Friedreichs Ataxia With Interferon Gamma-1b - - Company Currently Owns the Rights to Interferon Gamma- 1b Under the Trade Name ACTIMMUNE(r) in the United States, Canada and Japan - (May 19th, 2016)
DUBLIN, Ireland May 19, 2016 Horizon Pharma plc (NASDAQ: HZNP) (Horizon Pharma), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliate has entered into a definitive agreement with Boehringer Ingelheim International GmbH (Boehringer Ingelheim) to acquire the rights to interferon gamma-1b, which Boehringer Ingelheim commercializes under the trade names IMUKIN(r), IMUKINE(r), IMMUKIN(r) and IMMUKINE(r) in an estimated 30 countries primarily in Europe and the Middle East.